Journal Article

Crimean-Congo Hemorrhagic Fever

Sara Shayan, Mohammad Bokaean, Mona Ranjvar Shahrivar and Sadegh Chinikar

in Laboratory Medicine

Published on behalf of American Society for Clinical Pathology

Volume 46, issue 3, pages 180-189
Published in print August 2015 | ISSN: 0007-5027
Published online August 2015 | e-ISSN: 1943-7730 | DOI: https://dx.doi.org/10.1309/LMN1P2FRZ7BKZSCO
Crimean-Congo Hemorrhagic Fever

More Like This

Show all results sharing these subjects:

  • Clinical Cytogenetics and Molecular Genetics
  • Molecular and Cell Biology
  • Molecular Biology and Genetics

GO

Show Summary Details

Preview

Crimean-Congo hemorrhagic fever virus (CCHFV) is a member of the Bunyaviridae family and Nairovirus genus. The viral genome consists of 3 RNA segments of 12 kb (L), 6.8 kb (M), and 3 kb (S). Crimean-Congo hemorrhagic fever (CCHF) is the most widespread tickborne viral infection worldwide: it has been reported in many regions of Africa, the Middle East, and Asia. The geographical distribution of CCHFV corresponds most closely with the distribution of members of the tick genera, and Hyalomma ticks are the principal source of human infection. In contrast to human infection, CCHFV infection is asymptomatic in all species. Treatment options for CCHF are limited; immunotherapy and ribavirin are effective in the treatment of CCHF; the efficacy of ribavirin in the treatment of CCHF has not yet been proven. This article reviews the history, epidemiology, clinical symptoms, pathogenesis, diagnosis, and treatment of CCHFV, as well as the development of a vaccine against it.

Keywords: Crimean-Congo hemorrhagic fever virus (CCHFV); Arbovirus; tickborne viruse; zoonotic disease; epidemiology; pathogenesis and treatment of CCHF

Journal Article.  5959 words.  Illustrated.

Subjects: Clinical Cytogenetics and Molecular Genetics ; Molecular and Cell Biology ; Molecular Biology and Genetics

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content. subscribe or login to access all content.